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Abstract
Background: Trial research has predominantly focused on patient and staff understandings of trial concepts and/
or motivations for taking part, rather than why treatment recommendations may or may not be followed during
trial delivery. This study sought to understand why there was limited attainment of the glycaemic target (HbA1c
≤6.5%) among patients who participated in the Treating to Target in Type 2 Diabetes Trial (4-T). The objective was
to inform interpretation of trial outcomes and provide recommendations for future trial delivery.
Methods: In-depth interviews were conducted with 45 patients and 21 health professionals recruited from 11 of
58 trial centres in the UK. Patients were broadly representative of those in the main trial in terms of treatment
allocation, demographics and glycaemic control. Both physicians and research nurses were interviewed.
Results: Most patients were committed to taking insulin as recommended by 4-T staff. To avoid hypoglycaemia,
patients occasionally altered or skipped insulin doses, normally in consultation with staff. Patients were usually
unaware of the trial’s glycaemic target. Positive staff feedback could lead patients to believe they had been
‘successful’ trial participants even when their HbA1c exceeded 6.5%. While some staff felt that the 4-T automated
insulin dose adjustment algorithm had increased their confidence to prescribe larger insulin doses than in routine
clinical practice, all described situations where they had not followed its recommendations. Staff regarded the
application of a ‘one size fits all’ glycaemic target during the trial as contradicting routine clinical practice where
they would tailor treatments to individuals. Staff also expressed concerns that ‘tight’ glycaemic control might
impose an unacceptably high risk of hypoglycaemia, thus compromising trust and safety, especially amongst older
patients. To address these concerns, staff tended to adapt the trial protocol to align it with their clinical practices
and experiences.
Conclusions: To understand trial findings, foster attainment of endpoints, and promote protocol fidelity, it may be
necessary to look beyond individual patient characteristics and experiences. Specifically, the context of trial delivery,
the impact of staff involvement, and the difficulties staff may encounter in balancing competing ‘clinical’ and
‘research’ roles and responsibilities may need to be considered and addressed.
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Type 2 diabetes mellitus is a progressive disorder, with
many patients eventually requiring insulin therapy.
Alongside management of risk factors such as blood-
pressure, smoking and lipids, tight glycaemic control
significantly reduces the risks of diabetes-related micro-
and macro-vascular complications [1-3]. As a result of
these findings, health professionals have, until recently,
been encouraged to adopt aggressive approaches to con-
trolling blood glucose levels amongst their type 2 dia-
betes patients, including early initiation onto insulin.
The 4-T study was a large, 3-year multi-centre, open
label, UK-based randomized trial. It was developed
because of a lack of clinical knowledge at the time about
the most appropriate ways to initiate insulin therapies in
patients with type 2 diabetes, and how to help them
achieve optimal blood glucose control on intensive insu-
lin treatments. To do this, the trial evaluated and com-
pared the impact of three different licensed analogue
insulin regimens in patients amongst whom oral medica-
tion was no longer sufficient to maintain good glycaemic
control [4,5]. The three insulin regimens investigated
were basal (insulin determir, normally taken once a day),
biphasic (insulin aspart 30, taken twice daily) and pran-
dial (insulin aspart, taken three times a day), and were all
already widely used in routine clinical practice.
The trial employed a treat-to-target approach with a
glycaemic target of HbA1c ≤6.5%, in line with clinical
recommendations at the time of trial development [6,7].
This treat-to-target approach was used to help and
enable patients to achieve tight blood glucose control
and allow the different insulin regimens to be compared
in terms of ease of use, acceptability, clinical outcomes
(e.g. weight effects, risk of hypoglycemia and impact on
microalbuminuria), and patient adherence. A second
insulin formulation was added in the second and third
years if HbA1c levels of ≤6.5% were not achieved. To pro-
mote attainment of the trial’s glycaemic target, an on
online Trial Management System (TMS) was used in all
centres. Staff were required to enter patients’ clinical data
(e.g. weight, self-reported blood glucose readings over a
three day period, and reported episodes of hypoglycemia)
into the TMS. The TMS then employed a standardized
algorithm [8] to determine the insulin doses that needed
to be prescribed in order for patients to attain or main-
tain the glycaemic target, although, in the event of hypo-
glycaemia or other untoward factors, trial staff were
allowed occasional discretion in the prescription of insu-
lin doses. During the trial, patients received a compre-
hensive monitoring and support package comprising 17
clinic visits and at least 11 telephone contacts over three
years. Patients were also encouraged to alter insulin
doses themselves in between contacts and in response to
self monitoring of blood glucose (SMBG) readings
to help attain the trial target. The trial commenced
November 2004 and final closeout took place in July 2009.
Despite the intensive input provided during 4-T, there
was limited attainment of the glycaemic target across all
three treatment groups. At one year, 17% of the biphasic,
24% of the prandial and 8% of the basal group attained
an HbA1c ≤6.5%. At three years, the corresponding pro-
portions were 32%, 45% and 43% [4,5]. Similar outcomes
have been observed in other trials involving intensive
insulin therapies [9-12] and in routine clinical situations,
recent data indicating that control may be sub-optimal in
up to 75% of insulin-treated patients [13,14]. This has
prompted calls for the behavioral factors to be considered
and explored [5]. However, research has predominantly
focused on attitudes towards, and barriers to, initiating
insulin therapy [15-18]. There is a very limited under-
standing of how patients and health professionals per-
ceive and respond to tight glycaemic targets and the
issues and challenges encountered attaining or sustaining
tight glycaemic control after insulin treatment has been
initiated. Similarly, while there is an extensive trial litera-
ture, this has predominantly focused on patients’ motiva-
tions for trial participation [19-22] or patient and/or staff
understandings of randomization and/or equipoise
[23-25], and the implications of these for facilitating
recruitment and informed consent [19,26]. Little is
known about patients’ and health professionals’ experi-
ences of trial delivery and why treatments may or may
not be adhered to in the context of a clinical trial.
In this paper we report findings of an interview study
involving patients and health professionals who had par-
ticipated in 4-T. This study was conducted to under-
stand why there was limited attainment of the trial
target for glycaemic control across all three treatment
groups and over time. Key objectives were to inform
interpretation of trial outcomes and provide recommen-
dations for future trial delivery.
Methods
Qualitative methods are recommended when little is
known about the area of investigation. In-depth inter-
views were used in this study as these encourage partici-
pants to display their own understandings and meanings,
and permit themes and hypotheses which might not have
been anticipated to be identified and explored [27].
Recruitment and sample
Patients and staff were recruited from 11 of the 58 4-T
centres across the UK. Centres were selected to ensure
diversity in centre size, geographical location and pre-
vious trial involvement. Recruitment took place on trial
closeout. Patients and staff were sent information packs
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opted-in of which 45 were interviewed. Patients were
selected for interview on the basis of their treatment
type, age, gender and glycaemic control, so that the final
sample reflected the wider trial population in terms of
these characteristics (see Table 1). The patient sample
size (n = 45) was determined to allow a diversity of
experiences and views to be captured and explored in-
depth and for data saturation to occur in key areas (i.e.
for no new findings or themes to arise from an analysis
of new interviews) [28].
Twenty-one staff members were interviewed, the staff
sample including both physicians and research nurses
involved in trial delivery and at least one staff member
from each centre (see Table 1).
Data collection & analysis
Interviews took place between October 2008 and July
2009. These were informed by topic guides [see Appen-
dix 1] and conducted at a time and location selected by
participants. Interviews lasted 40-120 minutes, were
digitally recorded and transcribed verbatim. The study
was informed by the principles of grounded theory
which involves concurrent data collection and analysis,
together with systematic efforts to check and refine
developing categories of data [28,29]. Themes and
Table 1 Patient and staff characteristics
Patients 4T
(n = 708)
Qualitative sample (n = 45)
Age
Mean age (± SD) 61.7 (±9.8)* 64.7 (± 8.5)**
Sex
Male (%) 456 (64) 29 (64)
Female (%) 252 (36) 16 (36)
Randomisation
Biphasic (%) 235 (33) 15 (33)
Prandial (%) 239 (34) 15 (33)
Basal (%) 234 (33) 15 (33)
Glycaemic control at Yr 3
Median HbA1c 6.9% 6.9%
Number (%) of patients with HbA1c £ 6.5% 283 (40) 19 (42)
Number (%) of patients with HbA1c £ 7.0% 425 (60) 26 (58)
Health Care Professionals 4T ➢ Qualitative sample (n = 21)
Role
Physician (Phy) - 9
Research Nurse (RNs) - 12
Experience in diabetic medicine
0-5 years -1
10+ years -8
Clinical background in diabetic nursing prior to 4-T (e.g. Diabetes Specialist Nurse)
Yes -8
No -4
Nurse role during 4-T
Research only - 6
Research and clinical care - 6
Notes
Percentages rounded up to nearest whole number.
* Age at initiation of 4T.
** Age at interview.
➢ Trial data not available.
Lawton et al. Trials 2011, 12:108
http://www.trialsjournal.com/content/12/1/108
Page 3 of 10hypotheses identified in early interviews informed ques-
tions in later interviews. Team members independently
reviewed interview data and regular meetings were held
to explore participants’ underlying reasoning, discuss
deviant cases and reach agreement on recurrent themes
and findings. Interviews were coded to capture data
relating to the questions and areas explored in the topic
guides and emerging findings. QSR Nvivo 2, a qualita-
tive data-indexing package, was used to facilitate data
coding and retrieval.
At the point when data collection was stopped no new
themes were arising from an analysis of patient and staff
interviews. Data presented below are tagged with partici-
pants’ identifying number and status (P = Patient, RN =
Research Nurse, Phy = Physician).
The research was approved by the Hertfordshire
Research Ethics Committee (ref: 08/H0311/98). Written
informed consent was obtained from patients and staff
prior to their interviews. As part of the consent process,
patients and staff were informed that study findings
would be published in academic journals.
Results
Findings from the main 4-T trial showed that endpoint
glycated haemoglobin were similar for patients rando-
mised to biphasic (median: 7.1%), prandial (median: 6.8%)
and basal (median: 6.9%) insulin-based therapies (P =
0.28) [5]. Consistent with these findings, analysis of the
qualitative interviews did not reveal widespread or sys-
tematic differences in reported adherence amongst
patients in the three trial arms. Staff accounts, similarly,
did not reveal obvious differences in the treatment, advice
and care given to patients in different arms of the trial
(hence data reported below cut across the three trial
arms). However, whereas patients tended to present rela-
tively unproblematic accounts of participating in, and tak-
ing their insulin during, the trial, staff highlighted various
difficulties and dilemmas which arose during trial delivery.
In particular, staff described experiencing a conflict
between their roles and responsibilities as researchers and
clinicians. This conflict became most apparent when they
were required to treat to the trial’s tight glycaemic target.
Below, we begin with patients’ experiences of taking part
in 4-T before considering staff perspectives and views. We
will show that staff accounts need to be considered along-
side those of patients to fully understand why there was
limited attainment of the trial’s glycaemic target.
Patients’ experiences and views
Taking insulin during 4-T
As detailed elsewhere [30], virtually all patients described
being motivated and committed to taking their insulin
during the trial, as they perceived insulin as essential for
their diabetes control and long-term health: “if you don’t
take your medication, then that’si t ” (P31); “it’s a matter
of life and death” ( P 1 6 ) .H e n c e ,o n l yam i n o r i t yr e p o r t e d
extensive and intentional insulin non-adherence, the
most extreme case being P29 who stopped taking insulin
for three months after experiencing a severe hypoglycae-
mic episode requiring emergency services to be called
out:
“I’d never had a hypo before, but I’d been feeling
funny and I’ve maybe had a biscuit or something,
I’ve had something to eat and it went away but this
Sunday, for some reason, just after lunch, I just went
berserk, I nearly wrecked everything in the house.
And, of course, the wife panicked and she phoned
for the doctor and this emergency doctor came out,
because I was ranting and raving on and the wife
was panicking.” (P29)
While virtually all patients described sometimes for-
getting to inject insulin, particularly when daily routines
were disrupted, nearly half also talked about occasionally
adjusting and/or deliberately skipping doses. In almost
all cases, doses were altered or missed as a strategy to
curb or avoid hypoglycaemia; for instance, when a meal
was skipped or, in P10’s case, before undertaking
planned physical activity:
“If I’m going walking up the hills, I don’t take any, I
don’t take any Rapid insulin. Either that or I’db e
keeling over on the hills because my sugar levels,
with doing the extra exercise, my sugar levels would
be far too low... So I basically don’t take any. And at
the end of the day when I come back home, I check
my sugar level and it’s probably 6.5 or something
like that and that’s being out on the hills all day, eat-
ing as and when I needed.” (P10)
Some also described titrating insulin doses according
to foods consumed or in response to SMBG readings, to
avoid hypoglycaemia or optimise control:
“I now adjust my insulin with the blessing of, eh, my
blood sugar level. If they’re below six, I use eight
units in the morning. If they’re above six I use ten.
The only one I usually adjust is the morning one,
because if I don’t, I hypo.” (P21)
In almost all cases, patients described discussing these
strategies with 4-T staff and receiving their encourage-
ment and support.
Titration and intensification of treatment
Patients tended to defer to 4-T staff when decisions
were made about titrating and intensifying their insulin.
Some also recalled instances when they had been aware
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Patients described preferring to trust staff’sj u d g e m e n t
rather than the TMS, because of their holistic knowl-
edge of the patient, their ability to “use common sense”
(P11), and patients’ experiences of staff taking their per-
sonal circumstances into careful consideration:
“Computers are great for maths or something like
that but, for making decisions about people’sl i v e s ,
I’d rather have a human view point, that can weigh
it up, look at all angles.” (P20)
“I’d trust the nurse every time, cos everything was
fed into the computer and sent down to Oxford,
where as she was seeing me all of the time, what I’m
looking like healthwise etc.” (P22)
A minority, however, did describe becoming more
involved in negotiating their insulin doses with staff as
the trial progressed, prompted by experiences of hypo-
glycaemia which had led them to question or resist
TMS recommended doses:
“The information would be put in and generally it
w o u l dc o m eb a c ka n ds a yt om et h a tIn e e d e dt o
increase the dose by quite a substantial amount. But
actually the nurse knew I didn’t want to do that, that
I was wary to do it, and that also I am actually, I
believe, very sensitive to insulin, to having hypos...
And they were happy to reach a compromise; to dis-
cuss how I felt and then agree a path forwards.” (P11)
Trial targets
Most patients were unaware of the 4-T target for glycae-
mic control and determined their own success or failure
according to staff’s encouragement and responses to their
HbA1c results. In practice, this meant a patient could
think they had ‘done well’ even though they had not
reached the trial target, such as P2 who described how,
“once it was seven point something, they were all delighted
about it.” The reverse could also happen, such as when
P23 described how she had “felt a failure” despite getting
her HbA1c down to 6.4%, “because they were always trying
for 5.4, 5.6.”
Staff experiences and views
Treating to target
All staff expressed ambivalence about the trial target
(HbA1c ≤6.5) because it was tighter than normally
aimed for in routine clinical practice and recommended
in clinical guidelines. Some described feeling that “some-
times they were asking almost for people to be at too
high a risk of hypoglycaemia” (RN17). Others high-
lighted the lack of evidence of long-term benefits of
treating to a tight target: “over a 5 or 6 year period it
doesn’t seem to improve outcome to any great degree”
(Phy3), or commented that “there is some evidence that
if you do go too low, it can actually be dangerous”
(Phy7). The emphasis placed upon tight blood glucose
control rather than other risk factors was also ques-
tioned by some staff:
“We probably need to be much tougher on choles-
terol, much tougher on blood pressure em, and just
do the same as what we’re doing for glycaemic con-
trol. We’ve allowed our thinking about this, about
how glycaemic control can influence macrovascular
events, and they don’t really. It doesn’t really shape,
shape em, it’s not going to, it doesn’ts t o pp e o p l e
dying.” (Phy5)
Staff also expressed reservations about applying a ‘one
size fits all’ target to all patients commenting that, in clini-
cal practice, treatments would “be individualised to each
person” (Phy17). While tight targets were generally seen as
appropriate and realistic when patients were relatively
young, motivated/adherent and/or at risk of complications,
staff described being less keen to pursue tight targets
amongst the elderly, especially those who lived alone, and
those who did a lot of driving or physical activity:
“A tight target is realistic for anyone who is, its diffi-
cult to have a age cut off, but um sort of under the
age of 65, who is worried that high glucose levels will
damage their blood vessels, and who is up for enga-
ging in better control ... Contrast that with a very old
person with lots of other problems in whom you’re
not going to do them any favours by tightening up
their glucose levels. Because you’ve got to say to your-
self, ‘well, what are we actually going to achieve here
if we make then tight and them falling, and then
them being admitted with a fractured hip?’” (RN17)
“Some of them, because of their working lives, you
know, they travelled a lot, or they were builders doing
really physical work one day, maybe indoors and out-
doors and that seemed to vary it. And if they were
suddenly having lots of hypos sometimes you were
better erring on the side of caution and being higher
b e c a u s ea tl e a s tt h a tw a yt h e yc o u l ds t i l lw o r k ,s t i l l
function.” (RN19)
A st h ea b o v eq u o t e ss u g g e s t ,w o r r i e s“about patient
safety” (Phy17) were widely discussed by such staff
members. Some staff also raised concerns that increas-
ing patients’ risk of hypoglycaemia could potentially
undermine trust and the long-term therapeutic relation-
ship: “one hypo and they lose confidence in the system
and it’s very difficult to do anything with them.” (Phy9)
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a sense of failure in patients who had not reached the
t r i a lt a r g e tb u th a da c h i e v e d better control during 4-T.
This informed the decision that some had made to not
inform patients of the trial target.
Using the TMS
While generally considered a useful guide or starting
point for determining patients’ insulin doses, all staff,
especially those who came tot h et r i a lw i t he x t e n s i v e
diabetes clinical experience (see below), described regu-
lar deviations from the TMS’ recommendations because,
“it’s for sort of for ideal patients, and not every patient
is ideal” (Phy17). In most instances, deviations occurred
when, based on their clinical experience, which included
that of having previously used the insulins investigated
during 4-T, staff considered TMS recommended doses
to be too high and as putting a particular patient at risk
of hypoglycaemia:
“It h i n ki t ’s difficult really because I’ve been doing it
for x number of years and obviously was very com-
fortable with those particular insulins. And whether
it be a fault of the protocol or the system or just my
thinking, I don’t know, but it did make you stop and
think, ‘well that just seems too much.’” (RN13)
In a few cases, deviations were also a direct response
to patients’ resistance or refusal to have their insulin
doses increased after experiencing severe hypoglycaemia.
Staff described how this could result in a balancing act
“between keeping the patient in the study and trying to
fulfil the protocol as best as you could.” (RN13)
Some also conveyed concerns about the potentially
flawed and ‘untrustworthy’ data upon which the TMS’
recommendations were based. Nursing staff pointed out
that the three days of SMBG data fed into the TMS could
be a potentially inaccurate representation of a patient’s
blood glucose control over the previous months:
“But I’m looking back over quite a lot of readings, I
would make my decision on that rather than just
maybe the week the patient’sc o m i n gi n .B e c a u s e
you have other things, like maybe they’ve got a
stressful week on or, you, you know, you’ve got the
patient in front of you and you’ve got the diary in
front of you, you would sum up and then make your
decision.” (RN15)
Some also speculated that SMBG data might occa-
sionally have been fabricated by patients; typically
when diaries were presented in pristine condition. It
was also pointed out that the TMS did not factor in
for symptomatic hypoglycaemia above the trial’sS M B G
3.1 mmol/l threshold, or for experiences of ‘near
hypos’. Staff described how they would exercise their
own judgement on such occasions, drawing upon their
clinical experience:
“Because the thing is, we’d only write hypos in the
system, but sometimes patients would be talking
about near hypos and obviously there was no way of
recording that. So with that in mind, if they said,
‘oh, I always feel a touch lower before lunch’ blah
blah and they told you that quite a bit, there was no
way to record that... And then so you’dt h i n k‘well
I’m going to lower that then, that one, and then put
it up a bit more later’. But the TMS didn’tk n o w
that, so it would tell you different information and
then you’dg o“oh I’m not happy about that because
I think that would drop them down too low.”
(RN19)
While staff perceived the TMS as a potentially useful
tool for less experienced colleagues, such as those based
in general practice, some nursing staff said they had dis-
liked using it because they felt it had belittled and
undermined their expertise:
“I think for any insulin start trial, you know, you can
train a monkey to start insulin, but it takes some-
body with more in-depth knowledge to identify
where things are going wrong sometimes.” (RN2)
Other staff members, however, were more positive
about using this technology. They described their pre-
vious approach to managing insulin treated patients as
having been overly conservative and commented that
positive experiences of using the TMS had helped them
overcome their resistance to intensifying insulin treat-
ments in both the trial and in their clinical practice:
“We’ve always been used to rather more tentative
doses to start people on. So you know, we would
ordinarily have started people on 20 units a day and
the slide rule said you start on 40 in the morning
and 16 at night or something. Then you’re going to
s t e pb a c kal i t t l ef r o mt h a ta n dt h i n k‘hang on a
minute, that seems rather a lot to me’. But once you
got used to it, and learnt to trust it, then it seemed
to work most of the time.” (Phy14)
Negotiating the boundary between research and clinical
practice
“Working as a DSN and a research nurse, that is a
bit of an issue for me... I sometimes found myself in
ab i to fad i l e m m aw h e r eIt h i n k ,w e l lo f ft r i a l ,I
wouldn’t be doing this.” (RN2)
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interviews is the tension, and difficulties, encountered
when the trial protocol required them to deliver patient
care which differed from their routine clinical practice.
While staff talked about experiencing a conflict between
their roles as practitioners and researchers on such
occasions, the greatest dilemmas were conveyed by RNs.
W h i l et h i sw a sp a r t l yb e c a u s et h e yw e r er e s p o n s i b l ef o r
delivering most direct patient care during 4-T, many
RNs also came to the trial with extensive diabetes clini-
cal experience as they had worked and/or were continu-
ing to work part-time in a Diabetes Specialist Nurse
capacity alongside 4-T (see table 1). As various staff
members commented, the greater the RN’sd i a b e t e s
clinical experience the more likely they were to have
deviated from TMS recommended insulin doses during
the trial. RN6, for instance, who worked for a research
company and did not have a therapeutic speciality,
noted that, whilst she had “tended to just go for what
was suggested on the computer”, her more clinically
experienced colleagues:
“were just putting in what THEY thought were the
right doses and not going with the algorithm, the
protocol.” (RN6)
As well as deviating from the TMS’ recommendations,
clinically experienced RNs also offered patients extra
visits and/or input (e.g. dietary advice, training in carbo-
hydrate counting) to those outlined in the protocol, to
reflect the care they would provide in their diabetes
clinical practice. Some also indicated that they had given
patients extra services and enhanced clinical care (such
as a quick referral to a chiropody service) to foster treat-
ment adherence and trial retention.
Discussion
This study sought to understand why there was limited
attainment of the primary endpoint (HbA1c ≤6.5%) in the
Treating to Target in Type 2 Diabetes Trial (4-T). Patient
interviews did not reveal extensive and intentional acts of
treatment non-adherence which would have provided a
quick and easy answer to this question. To the contrary,
patients generally made efforts to adhere to their insulin
regimens during the trial, in some cases by skipping or
titrating doses to avoid hypoglycaemia. Some also
believed they had done well during the trial despite not
reaching the glycaemic target. While previous research
has attempted to explain poor adherence to diabetes and
other treatments by focusing upon individual patient
characteristics, experiences and life circumstances [31],
this study highlights the importance of considering the
perspectives and experiences of staff. By locating patients’
accounts alongside those of 4-T staff, this study has
highlighted how staff mediated and buffered patients’
experiences of using insulin treatments during the trial,
their perceptions of success, and their awareness of the
trial target. It has further been shown that the potential
impact of staff behaviours on trial outcomes arose in part
from the conflict they experienced between their roles
and responsibilities as researchers and practitioners and
from the requirement to follow a protocol which sought
to standardise practice. While they sometimes addressed
this conflict by revising their clinical practice in light of
trial experiences (e.g. saying they would prescribe larger
insulin doses after using the TMS), more frequently, and
especially when staff came to the trial with diabetes clini-
cal experience, they adapted the trial protocol to align it
with their clinical practices and experiences. This led to
instances of staff not following the TMS when recom-
mended doses were perceived as presenting risks to
patient trust and safety, or offering patients enhanced
care outwith the protocol. While such interventions may
have helped to curb or mitigate intentional treatment
non-adherence by patients and/or to foster trial reten-
tion, they also appear to be a major factor responsible for
the limited attainment of the 4-T glycaemic target.
Staff ambivalence about using decision support soft-
ware and following standardised algorithms has been
observed in other healthcare settings, particularly when
recommendations contradict professional judgement
arising from clinical experience [32,33]. Hence staff
attempts to tailor and individualise patient care during
4-T may not simply have been a consequence of working
in a trial setting, and may reflect a more general difficulty
health professionals encounter when required to follow
protocols and clinical guidelines which seek to regulate
and standardize their practice [34]. Like this study,
research has also found that triallists may struggle to
exchange their role of providers of individualised care
with that of researchers required to follow standardised
trial procedures [25,35], resulting, for instance, in the
provision of a ‘quasi-clinical service’ in the research set-
ting [35,36]. However, while many trials involve new
treatments, the insulin therapies compared in 4-T were
already widely used in clinical practice. Hence 4-T staff
may have had more clinical experience to draw upon
than is typical in a trial and may have experienced a
greater role conflict as a consequence. Indeed, the data
suggest that a large part of staff ambivalence about their
participation in 4-T arose from the trial’s requirement to
treat to a lower target than that routinely used in their
clinical practice. Hence the timing of the trial and its
location within UK may have impacted on its outcomes.
In the UK, management of type 2 diabetes is strongly
influenced by the requirements of the UK quality and
outcomes framework (QOF). Until recently, the finan-
cially incentivised target set by QOF was 7.5%. While the
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EASD recommendations, it is still higher than that used
in 4-T and recommended in other countries [6,7].
Furthermore, it must be noted that, for reasons of patient
safety, 4-T staff were allowed a limited degree of leeway
in prescribing the dosage as recommended by the TMS.
A degree of discretion is often built into protocols of
pragmatic trials and complex interventions. However,
granting 4-T staff the scope to adjust the TMS’ recom-
mendations may have been interpreted by some, particu-
larly the more clinically experienced, as permission to
individualise treatments more widely than was originally
intended by those who designed the trial.
While the specific context of 4-T delivery needs to be
taken into account, this study does raise important issues
for the conduct of future trials, especially those, such as 4-
T, where staff may be required to follow procedures to
assess individual patient safety before implementing man-
dated therapy changes. Fidelity to protocols is essential for
successful trial delivery [38] and this study, alongside
others [25,39], highlights the importance of exploring, and
addressing, staff perspectives and views. One way to avoid
or resolve the role conflict highlighted by 4-T staff and
observed elsewhere [35,36] may be to appoint front-line
staff who do not have an extensive clinical background or
training in the specific area of trial investigation. However,
this approach may not be feasible as changes in the
research environment have resulted in an increased reli-
ance on nurses working on trials who have primarily clini-
cal rather than research experience. While trial staff might
benefit from greater regulation and oversight to foster pro-
tocol adherence, such as the recording and feedback of the
frequency of their overrides, it has already been shown
that these regulatory procedures are unlikely to curb indi-
vidual decision-making and ensure standardization of
practice [33]. Hence multifaceted interventions may be
needed to support staff, reduce ambiguity in the courses of
action they perceive as open to them [40], and help them
‘suspend belief’ and provide treatment in accordance with
a protocol which may be outside current guidelines of
standard clinical care. This may include the provision of
more training and education in principles of trial design,
aims, and methods, to promote a better understanding of
why trial protocols need to be followed and of concepts
such as equipoise [25]. Since increasing numbers of clini-
cal staff are becoming involved in clinical trials, this type
of education could be made an integral part of all specia-
list nurse training. Another approach which has already
been used to support delivery of trials involving complex
interventions is to set aside resources to help promote
protocol fidelity. These include extensive training aligned
t oam a n u a l ,u s eo fr o l ep l a yt oe n s u r ef a m i l i a r i t y
with options available in the protocol, recording of
interventions, and review of these recordings with a lead
facilitator or supervisor to discuss best practice in follow-
ing the protocol [41,42]. However, this type of approach
may be complex and costly to deliver. An alternative is to
focus on leadership of research in the clinical setting. One
w a yt od ot h i sw o u l db et oa p p o i n tac a d r eo fs e n i o r
research staff who are not directly involved in trial delivery
and are available to provide regular support to research
nurses. In providing support and supervision, it would be
possible to identify issues arising during trial delivery and
help resolve them. The building of qualitative work into
the early stages of a trial may also be an effective way of
identifying staff dilemmas and/or better ways of delivering
a trial to promote adherence and retention [43].
A key strength of this study, as already indicated, is that
it drew upon the perspectives of staff as well as patients,
enabling a clear and comprehensive understanding to be
gained of why there was limited attainment of the trial’s
primary endpoint. Indeed, we would recommend that
multiple perspectives (staff and patient) are considered in
all future work seeking to understand and/or promote
treatment adherence, whether this be in a trial or clinical
setting. The use of a multi-site recruitment strategy,
which is unusual in qualitative research, increases the
potential generalisability of the findings. By using an opt-
in procedure (a medical ethics committee requirement),
and only interviewing trial completers, the sample may
have been biased towards patients with more positive, or
extreme, experiences of the trial and injecting insulin.
However, this potential limitation was overcome by pur-
posively selecting a patient sample broadly representative
of trial participants in terms of glycaemic control and
(non-)attainment of the trial’s glycaemic target.
Conclusions
There is a growing trend towards trials which involve the
use of licensed treatments, as well as those in which staff
are allowed some discretion in exercising or following a
protocol (e.g. trials involving complex interventions). As
4-T is a good example of this trend, this study has wide
relevance for the rigor with which future trials can be
delivered and provides important insights into some of
the issues faced by trial staff. The findings highlight that
t h ed e l i v e r yo ft r i a l ss u c ha s4 - Tc a nb ea f f e c t e db yw h a t
are currently poorly recognised and debated issues, such
as role conflicts experienced by trial staff. These conflicts
may be exacerbated when trial protocols are implemen-
ted by staff who undertake clinical work alongside, and/
o ri nt h es a m ea r e aa s ,t h et r i a l .O u rf i n d i n g ss u g g e s t
that, to promote fidelity to trial protocols, front line staff
may benefit from more education, training and support,
especially when they are required to provide treatment
which is outside current guidelines of standard clinical
Lawton et al. Trials 2011, 12:108
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Page 8 of 10care. Similarly, involving clinical staff in the development
of trial protocols and procedures may help limit the pos-
sibility of tensions arising during trial delivery.
Appendix 1
Key topics explored in patient interviews
￿ Treatment history (from diagnosis to referral for
insulin).
￿ Reasons for participating in 4-T; experiences of
trial participation (including likes/dislikes of proce-
dures used and guidance received).
￿ Perceptions and understandings of the trial; per-
ceptions/awareness of trial targets for glycaemic
control.
￿ Reasons for adhering/not adhering to insulin and
other treatments during the trial.
￿ Involvement in treatment changes and dose adjust-
ment decisions.
￿ Reasons for remaining in the trial; perceived
impact of trial participation on diabetes control, gen-
eral health and quality of life.
Key topics explored in patient interviews
￿ Training and background; reasons for involvement
in 4-T.
￿ Perceptions and understandings of the trial and
trial target.
￿ Experiences of initiating and titrating insulin in
type 2 patients (in both routine care settings and as
part of clinical trials).
￿ Experiences of delivering 4-T (from initial meet-
ings and patient recruitment to trial close-out); dif-
ferences between care delivered during 4-T and in
routine clinical practice.
￿ Views about treating to target and using the TMS;
reasons for following/not following the TMS’s
recommendations.
￿ Reflections on the implications of 4-T findings for
clinical practice.
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